Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$56.27 - $73.77 $562 - $737
-10 Reduced 17.86%
46 $3,000
Q4 2023

Feb 12, 2024

BUY
$59.06 - $75.72 $590 - $757
10 Added 21.74%
56 $4,000
Q3 2023

Nov 07, 2023

SELL
$65.94 - $99.04 $461 - $693
-7 Reduced 13.21%
46 $3,000
Q2 2023

Jul 28, 2023

BUY
$62.68 - $95.05 $438 - $665
7 Added 15.22%
53 $4,000
Q4 2022

Feb 10, 2023

BUY
$30.35 - $53.15 $1,396 - $2,444
46 New
46 $2,000
Q2 2022

Aug 05, 2022

SELL
$35.61 - $76.23 $3,276 - $7,013
-92 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$72.5 - $100.68 $652 - $906
9 Added 10.84%
92 $7,000
Q3 2021

Nov 10, 2021

SELL
$90.24 - $124.05 $1,534 - $2,108
-17 Reduced 17.0%
83 $8,000
Q2 2021

Aug 11, 2021

SELL
$93.66 - $139.27 $280 - $417
-3 Reduced 2.91%
100 $12,000
Q1 2021

May 13, 2021

SELL
$116.57 - $155.01 $932 - $1,240
-8 Reduced 7.21%
103 $14,000
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $2,789 - $3,979
28 Added 33.73%
111 $15,000
Q2 2020

Aug 13, 2020

SELL
$55.75 - $92.75 $6,021 - $10,017
-108 Reduced 56.54%
83 $7,000
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $107,446 - $296,087
-2,835 Reduced 93.69%
191 $11,000
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $13,046 - $16,756
-168 Reduced 5.26%
3,026 $280,000
Q3 2019

Nov 13, 2019

BUY
$90.37 - $122.49 $40,485 - $54,875
448 Added 16.31%
3,194 $288,000
Q2 2019

Jul 09, 2019

BUY
$89.51 - $118.04 $22,735 - $29,982
254 Added 10.19%
2,746 $325,000
Q1 2019

May 10, 2019

BUY
$61.98 - $96.5 $154,454 - $240,478
2,492 New
2,492 $216,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $11.9B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Zions Bancorporation, N.A. Portfolio

Follow Zions Bancorporation, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Zions Bancorporation, N.A. with notifications on news.